CN101497652B - 一种抑制实体肿瘤及白血病癌细胞生长的肽类及其应用 - Google Patents
一种抑制实体肿瘤及白血病癌细胞生长的肽类及其应用 Download PDFInfo
- Publication number
- CN101497652B CN101497652B CN2008100705844A CN200810070584A CN101497652B CN 101497652 B CN101497652 B CN 101497652B CN 2008100705844 A CN2008100705844 A CN 2008100705844A CN 200810070584 A CN200810070584 A CN 200810070584A CN 101497652 B CN101497652 B CN 101497652B
- Authority
- CN
- China
- Prior art keywords
- cancer
- nucleotide
- dna
- amino acid
- small peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 84
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 81
- 201000011510 cancer Diseases 0.000 title claims abstract description 45
- 208000032839 leukemia Diseases 0.000 title claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 title abstract description 8
- 230000010261 cell growth Effects 0.000 title 1
- 239000002773 nucleotide Substances 0.000 claims abstract description 113
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 113
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000036210 malignancy Effects 0.000 claims abstract description 4
- 206010020718 hyperplasia Diseases 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- UMIRPYLZFKOEOH-YVNDNENWSA-N Glu-Gln-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UMIRPYLZFKOEOH-YVNDNENWSA-N 0.000 claims 1
- WLIPTFCZLHCNFD-LPEHRKFASA-N Glu-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O WLIPTFCZLHCNFD-LPEHRKFASA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 51
- 102000007079 Peptide Fragments Human genes 0.000 abstract description 6
- 108010033276 Peptide Fragments Proteins 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 239000003560 cancer drug Substances 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 abstract description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 210000001167 myeloblast Anatomy 0.000 abstract 1
- 239000012434 nucleophilic reagent Substances 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 76
- 235000001014 amino acid Nutrition 0.000 description 52
- 238000000034 method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- -1 Gla amino acid Chemical class 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- IYPRWQPJYRBHIS-UHFFFAOYSA-N acetic acid;uranium Chemical compound [U].CC(O)=O IYPRWQPJYRBHIS-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- WTZUSCUIVPVCRH-SRVKXCTJSA-N Lys-Gln-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WTZUSCUIVPVCRH-SRVKXCTJSA-N 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000006778 chronic monocytic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100705844A CN101497652B (zh) | 2008-02-01 | 2008-02-01 | 一种抑制实体肿瘤及白血病癌细胞生长的肽类及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100705844A CN101497652B (zh) | 2008-02-01 | 2008-02-01 | 一种抑制实体肿瘤及白血病癌细胞生长的肽类及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101497652A CN101497652A (zh) | 2009-08-05 |
CN101497652B true CN101497652B (zh) | 2011-04-06 |
Family
ID=40944939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100705844A Expired - Fee Related CN101497652B (zh) | 2008-02-01 | 2008-02-01 | 一种抑制实体肿瘤及白血病癌细胞生长的肽类及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101497652B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2960542B1 (fr) * | 2010-05-27 | 2012-08-17 | Esther Suzy Arlette Fellous | Peptide en tant que medicament, en particulier pour le traitement du cancer |
CN104017052B (zh) * | 2014-06-25 | 2016-07-06 | 山东兴瑞生物科技有限公司 | 关于Npas2蛋白激动剂多肽及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1724561A (zh) * | 2005-07-21 | 2006-01-25 | 李�昊 | 促进骨髓有核细胞及骨髓基质细胞增殖的系列肽及其应用 |
-
2008
- 2008-02-01 CN CN2008100705844A patent/CN101497652B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1724561A (zh) * | 2005-07-21 | 2006-01-25 | 李�昊 | 促进骨髓有核细胞及骨髓基质细胞增殖的系列肽及其应用 |
Non-Patent Citations (1)
Title |
---|
李昊等.生物活性肽自动查询预测系统.《生物信息学》.2006,(第4期),176-181. * |
Also Published As
Publication number | Publication date |
---|---|
CN101497652A (zh) | 2009-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112386678B (zh) | 多肽或其衍生物的应用 | |
US20220389060A1 (en) | Synthetic peptide sp2 and application thereof | |
CN105531284A (zh) | 细胞穿透肽和包含其的缀合物 | |
KR102279429B1 (ko) | 멀티 암 표적 항암 콘쥬게이트 | |
US20220332761A1 (en) | Synthetic peptide sp4 and use thereof | |
CN104177500B (zh) | 一种肿瘤坏死因子相关凋亡配体融合蛋白及其制法和用途 | |
CN101497652B (zh) | 一种抑制实体肿瘤及白血病癌细胞生长的肽类及其应用 | |
Mizejewski et al. | Update of alpha fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor growth and metastasis | |
CN101225106B (zh) | 一种抑制癌细胞生长的短肽及其应用 | |
CN106188244B (zh) | 抑制癌细胞活性的短肽治疗剂及含有它的医药组合物 | |
CN101497653B (zh) | 一种抑制实体肿瘤及白血病癌细胞生长的短肽及其应用 | |
CN108727583A (zh) | 多臂靶向抗癌偶联物 | |
CN116715723A (zh) | 一种抑制血管生成的小分子短肽及其在制备抗肿瘤药物中的应用 | |
CN113583095B (zh) | 抗肿瘤多肽及其用途 | |
CN101824072A (zh) | 一种抑制实体肿瘤及白血病癌细胞生长的短肽及其应用 | |
CN111534502B (zh) | 一种抗癌活性蛋白妙沙林及其编码基因和应用 | |
CN111138515B (zh) | 一种靶向FGFRs的抗肿瘤小分子多肽及应用 | |
CN101092452A (zh) | 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法 | |
CN106466484B (zh) | 一种具有细胞内吞介导功能的多靶向配体-药物偶联体 | |
CN101235079A (zh) | 一种抑制肝癌细胞生长的短肽系列及其应用 | |
CN109666064A (zh) | SALL4-RBBp4复合物阻断多肽和衍生抗肿瘤多肽及其应用 | |
CN106754805B (zh) | 一种抗肿瘤多肽及其制备方法和用途 | |
CN101270151B (zh) | 一种促进骨髓造血细胞增殖的肽类药物 | |
JP7194928B2 (ja) | 抗腫瘍ペプチドおよびその利用 | |
CN106928325B (zh) | 增强肝癌细胞对cik细胞杀伤敏感性的人工多肽及其生物制品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LI HONGQUAN Free format text: FORMER OWNER: LI HAO Effective date: 20111213 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 350002 FUZHOU, FUJIAN PROVINCE TO: 110015 SHENYANG, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20111213 Address after: 110015 China Shenyang city Shenhe District Wanliutanglu No. 25 Patentee after: Li Hongquan Address before: 350002, No. 607, No. 8, No. 118 West 2nd Ring Road, Taijiang District, Fujian, Fuzhou Patentee before: Li Hao |
|
ASS | Succession or assignment of patent right |
Owner name: SHENYANG YIHONG INFORMATION TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LI HONGQUAN Effective date: 20120605 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120605 Address after: Wanliutang road in Shenhe District of Shenyang City, Liaoning Province, No. 53, 110015 China Patentee after: Shenyang Yihong Information Technology Co.,Ltd. Address before: 110015 China Shenyang city Shenhe District Wanliutanglu No. 25 Patentee before: Li Hongquan |
|
CP03 | Change of name, title or address |
Address after: 110046 room 3602, Changfeng center, 22 Peng Jiang Street, Dadong District, Shenyang, Liaoning. Patentee after: Yihong Technology Co.,Ltd. Address before: No. 53, Wanliu Tong Road, Shenhe District, Shenyang, Liaoning Patentee before: Shenyang Yihong Information Technology Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210805 Address after: 350109 building 4, new drug creation center, high tech Zone, Fuzhou, Fujian Patentee after: Li Hao Address before: 110046 room 3602, Changfeng center, 22 Peng Jiang Street, Dadong District, Shenyang, Liaoning. Patentee before: Yihong Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110406 Termination date: 20220201 |
|
CF01 | Termination of patent right due to non-payment of annual fee |